Merve Alaylıoğlu

Merve Alaylıoğlu

Auto-generated profile, based on publicly available information

Merve Alaylıoğlu

Brain and Neurodegenerative Disorders Research Laboratories, Department of Neuroscience, Institute of Neurological Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
DGDuygu Gezen-Ak
Duygu Gezen-Ak
MAMerve Alaylıoğlu
Merve Alaylıoğlu
ZYZuhal Yurttaş
Zuhal Yurttaş
TÇTugay Çamoğlu
Tugay Çamoğlu
BŞBüşra Şengül
Büşra Şengül
EDErdinç Dursun
Erdinç Dursun

21 March 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PSPelin Sordu
Pelin Sordu
MAMerve Alaylıoğlu
Merve Alaylıoğlu
BSBedia Samancı
Bedia Samancı
EBErsel Bulu
Ersel Bulu
ZGZeynep Ece Kaya Güleç
Zeynep Ece Kaya Güleç
DGDuygu Gezen-Ak
Duygu Gezen-Ak
Background: The data that we gathered from a protein-protein interaction (PPI) prediction tool, FpClass, and a limited number of studies indicated that the chaperones HSP90AA1, HSPA4, STUB1/CHIP might interact with amyloid-β (Aβ) and/or tau and could subsequently be co-released into the cerebrospinal fluid (CSF). Therefore, we investigated CSF levels of HSP90AA1, HSPA4, and STUB1/CHIP in Alzheimer's disease (AD), Non-AD mild cognitive impairment (Non-AD MCI), and frontotemporal dementia (FTD) cases. Methods: The CSF levels of HSP90AA1, HSPA4, STUB/CHIP, and core AD biomarkers were determined by ELISA in AD (n = 90), Non-AD MCI (n = 27), FTD (n = 15), and subjective cognitive impairment (SCI) (n = 20) subjects. Results: HSP90AA1 levels were significantly higher in AD cases compared to the SCI subjects. The CSF levels of STUB1/CHIP were significantly lower in AD, Non-AD MCI and FTD cases compared to the SCI subjects. STUB1/CHIP levels of FTD cases were significantly lower than all other groups. HSPA4 levels was correlated with core AD biomarkers (Aβ 1–42, p-Tau, t-Tau) regardless of disease. Non- APOE ε4 carrier FTD cases also had significantly lower STUB1/CHIP levels than other groups. Conclusions: The STUB1/CHIP holds promise as a potential biomarker for distinguishing between SCI subjects, AD, and FTD. Furthermore, APOE might serve as an additional discriminatory factor that might be integrated with this chaperone for enhanced discrimination.

1 July 2018 in Alzheimer's & Dementia
Verified
Journal Article
Open access
EDErdinç Dursun
Erdinç Dursun
MAMerve Alaylıoğlu
Merve Alaylıoğlu
IAIrem L. Atasoy
Irem L. Atasoy
BSBusra Sengul
Busra Sengul
EBEzgi Soncu Buyukiscan
Ezgi Soncu Buyukiscan
DGDuygu Gezen-Ak
Duygu Gezen-Ak

20 March 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
GAGülsel Ayaz
Gülsel Ayaz
PSPelin Sordu
Pelin Sordu
UKUmut Can Küçüksezer
Umut Can Küçüksezer
HHHaşmet Hanağası
Haşmet Hanağası
MAMerve Alaylıoğlu
Merve Alaylıoğlu
TUTurgut Ulutin
Turgut Ulutin
Background: Alterations in biochemical and molecular pathways in Alzheimer's disease (AD) may be evident in the brain, blood cells, and vessels. Platelets regulate blood hemostasis and play key roles in neurodegenerative diseases like AD. miR-26a-5p and GP1b may affect platelet functions (PF), with miR-26a-5p as a diagnostic/therapeutic target and GP1b linking vascular and neurological disorders in AD progression. Objective: This study explores the roles of GP1b and hsa-miR-26a-5p in regulating PF in AD. Methods: 85 participants, including 43 AD, and 45 controls, were included. PF induced by ADP were assessed by optical density and white matter changes by MRI Axial FLAIR. Serum levels of von Willebrand Factor and GP1b were measured by ELISA. Platelet receptor expressions of CD62P and CD42b (GPIb) were measured by flow cytometry, and levels of hsa-miR-26a-5p and hsa-miR-24-3p by qRT-PCR. Results: ADP-induced PF was significantly reduced in AD (p = 0.016). Flow cytometry showed significantly low CD42b and high CD62P expression in AD, respectively (p < 0.0001, p = 0.014). Serum GP1b levels were significantly higher in AD (p = 0.018). Additionally, hsa-miR-26a-5p expression was significantly low in AD (p = 0.001), and a positive correlation was found between the expression levels of hsa-miR-24-3p and hsa-miR-26a-5p in both controls; and AD (r = 0.4149, p = 0.0051, 95% CI = 0.1256–0.6392; r = 0.6820, p = 0.0023, 95% CI 0.4728–0.8184). Conclusions: This study highlights increased serum GP1b levels with decreased both platelet surface GP1b levels and hsa-miR-26a-5p expressions in AD. GP1b and hsa-miR-26a-5p might have essential roles on PF in AD.

28 May 2024
Verified
Book Chapter
Closed access
DGDuygu Gezen-Ak
Duygu Gezen-Ak
MAMerve Alaylioglu
Merve Alaylioglu
TCTugay Camoglu
Tugay Camoglu
ZYZuhal Yurttas
Zuhal Yurttas
BYBusra Sengul Yediel
Busra Sengul Yediel
EDErdinç Dursun
Erdinç Dursun
This section provides practical knowledge about the molecular structures, clinical use conditions, and laboratory applications of biomarkers, focusing on those currently in use, soon to be used, and those with high potential. Main biomarkers for AD diagnosis include Aβ fragments, tau protein forms, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and alpha-synuclein (αSyn). Aβ fragments, central to AD pathology, are released by the cleavage of amyloid-beta precursor protein (APP). They form amyloid plaques and can be detected in cerebrospinal fluid (CSF) and plasma, with specific ratios aiding in diagnosis. Tau proteins, particularly phosphorylated tau (p-tau) and total tau (t-tau), reflect neurofibrillary tangles and neurodegeneration. NfL, a marker of axonal damage, and GFAP, indicative of reactive astrogliosis, are measured in CSF and blood. αSyn, associated with synucleinopathies, forms aggregates detectable in biological samples. Detection methods include conventional immunodetection techniques like ELISA, ultrasensitive technologies like SIMOA, and amyloid seed amplification assays (SAA). These methods enable the accurate measurement of biomarkers, enhancing early diagnosis and monitoring of AD.

16 April 2026 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
SDSibel Demirci Delipinar
Sibel Demirci Delipinar
HEHakan Ekmekci
Hakan Ekmekci
ZGZeynep Banu Güngör
Zeynep Banu Güngör
DGDuygu Gezen-Ak
Duygu Gezen-Ak
MAMerve Alaylioglu
Merve Alaylioglu
ISIsmail Seckin
Ismail Seckin